Evidence map›Paper›PMID 39219190›Full record

ArticleCancer medicine2024

Effect of nucleos(t)ide analogue discontinuation on the prognosis of HBeAg-negative hepatitis B virus-related hepatocellular carcinoma after hepatectomy: A propensity score matching analysis.

Ting Sun, Yiwen Qiu, Tao Wang, Yi Yang, Haizhou Qiu, Shu Shen, Huasheng Pang, Wentao Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ting SunDivision of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.
Yiwen QiuDivision of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.
Tao WangDivision of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.
Yi YangDivision of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.
Haizhou QiuDivision of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.
Shu ShenDivision of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.
Huasheng PangTibet Center of Disease Control and Prevention, Tibet Autonomous Region, Lhasa, P. R. China.
Wentao WangDivision of Liver Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, P. R. China.ORCID 0000-0002-6966-2665

Funding

Health Commission of the Tibet Autonomous Region 311220432National Natural Science Foundation of China 82000599National Natural Science Foundation of China 82170543NHC Key Laboratory of Echinococcosis Prevention and Control 2021WZK1004Science and Technology Program of Sichuan Science and Technology Department 2019YFS0576Science and Technology Program of Sichuan Science and Technology Department 2023YFS0229
6 · The paper itself

Abstract

backgroundAlthough nucleos(t)ide analogues (NAs) are thought to reduce the risk of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), the effect of NA discontinuation on the prognosis of HBV-related HCC after hepatectomy is rarely reported. We aimed to investigate the potential for hepatitis B virus e antigen (HBeAg)-negative HBV-related HCC patients to discontinue NAs based on preoperative hepatitis B virus surface antigen (HBsAg) status.

methodsThis historical cohort study involved 1232 NA-treated HBeAg-negative patients who underwent curative hepatectomy for HBV-related HCC from 2014 to 2019. The recurrence-free survival (RFS) and overall survival (OS) of patients discontinuing NAs before surgery were compared with those continuing NAs. Propensity score matching (PSM) was used to balance baseline characteristics.

resultsOf all enrolled patients, 839 (68.1%) patients continued NAs, and 393 (31.9%) patients discontinued NAs. Continuation of NAs was identified as an independent risk factor for RFS (HR 2.047, 95% CI 1.348-3.109, p < 0.001 before PSM and HR 2.756, 95% CI 1.537-4.942, p < 0.001 after PSM) in HBsAg-negative patients. Similarly, subgroup survival analyses showed that NA discontinuation was associated with better RFS (p = 0.029 before PSM and p < 0.001 after PSM) and comparable OS (p = 0.935 before PSM and p = 0.115 after PSM) than NA continuation in HBsAg-negative patients. The interaction between HBsAg status and continuation or discontinuation of NAs was significant (p for interaction <0.001).

conclusionsThese findings demonstrate the potential for HBeAg-negative HBV-related HCC patients who have achieved HBsAg seroclearance to discontinue NAs under strict monitoring.

Indexed as

Carcinoma, HepatocellularHepatectomyHepatitis B e AntigensHepatitis B virusLiver NeoplasmsPropensity ScoreAdultAgedAntiviral AgentsFemaleHepatitis B, ChronicHepatitis B Surface AntigensHumansMaleMiddle AgedNucleosidesAntiviral AgentsHepatitis B e AntigensHepatitis B Surface AntigensNucleosidesdiscontinuationhepatitis B virushepatitis B virus surface antigenhepatocellular carcinomanucleos(t)ide analoguestreatment outcome

Identifiers

PMID39219190
PMCPMC11366777

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.